PICALM Genetic Variant Alters mRNA Expression Without Affecting Protein Levels or Tau Spreading in Alzheimer's
Kunie Ando1, Lidia Lopez-Gutierrez1, Salwa Mansour2
1Alzheimer and Other Tauopathies Research Group, ULB Center for Diabetes Research, Medical Faculty, ULB Neuroscience Institute, Université Libre de Bruxelles (ULB), 808 Route de Lennik, B-1070 Brussels, Belgium.
Abstract:
Phosphatidylinositol-binding clathrin assembly protein (PICALM) is a clathrin adaptor essential for clathrin-mediated endocytosis. Genome-wide association studies (GWAS) have consistently identified PICALM as one of the most significant genetic susceptibility loci for late-onset sporadic Alzheimer's disease (AD). However, the functional impact of the most validated AD-associated variant, rs3851179, remains unclear. Here, we examined PICALM mRNA and protein expression in post-mortem AD brains with reference to rs3851179 genotype. We found that PICALM mRNA levels were significantly increased in AD brains compared with controls, and that the protective rs3851179T allele was associated with reduced PICALM mRNA levels relative to the non-protective rs3851179C allele. In contrast, PICALM levels were significantly reduced in AD brain lysates compared with controls. PICALM expression did not significantly differ between carriers of the protective and non-protective alleles. Analysis of the mRNA-to-protein ratio revealed a significant dissociation between transcript and protein levels, suggesting relatively reduced protein expression efficiency in cases carrying the non-protective CC genotype. To assess whether reduced PICALM levels influence tau pathology, we used Picalm heterozygous knockout (Picalm+/-) mice, which express approximately 50% of the wild-type Picalm protein. Following stereotaxic injection of pathological tau extracted from AD brains, both wild-type and Picalm+/- mice developed tau pathology; however, the extent of tau accumulation did not significantly differ between genotypes. Together, these findings indicate that although PICALM protein level is reduced in AD, this reduction does not appear to affect tau propagation in this model. Therefore, the AD susceptibility associated with PICALM variant likely arises from mechanisms other than tau spread, possibly involving other aspects of autophagy, endocytic or vascular function.
Insights
Alzheimer
Area of Science:
- Neuroscience
- Genetics
- Molecular Biology
Background:
- Genome-wide association studies consistently link PICALM to Alzheimer's disease (AD) risk.
- The functional impact of the AD-associated variant rs3851179 in PICALM remains unclear.
- PICALM is a clathrin adaptor protein crucial for endocytosis.
Purpose of the Study:
- To investigate the expression of PICALM mRNA and protein in post-mortem Alzheimer's disease (AD) brains.
- To examine the relationship between the AD-associated variant rs3851179 and PICALM expression levels.
- To assess the impact of reduced PICALM levels on tau pathology in a mouse model.
Main Methods:
- Analysis of PICALM mRNA and protein levels in post-mortem AD brains stratified by rs3851179 genotype.
- Measurement of mRNA-to-protein ratios to assess expression efficiency.
- Utilizing Picalm heterozygous knockout mice to model reduced PICALM levels and assess tau pathology after stereotaxic injection of pathological tau.
Main Results:
- PICALM mRNA levels were elevated in AD brains, with the protective rs3851179T allele associated with lower mRNA levels.
- PICALM protein levels were reduced in AD brains.
- A dissociation between mRNA and protein levels was observed, indicating reduced protein expression efficiency in carriers of the non-protective CC genotype.
- Reduced PICALM levels in mice did not significantly alter tau pathology progression.
Conclusions:
- PICALM protein is reduced in Alzheimer's disease (AD) brains, but this reduction does not appear to influence tau pathology spread in the studied mouse model.
- The Alzheimer's disease (AD) susceptibility associated with PICALM variants likely involves mechanisms beyond tau propagation, potentially related to endocytic, vascular, or autophagy functions.
More Related Videos
09:12Modulation of Tau Subcellular Localization as a Tool to Investigate the Expression of Disease-related Genes
Published on: December 20, 2019
10:38Using Live-Cell Imaging to Measure the Effects of Pathological Proteins on Axonal Transport in Primary Hippocampal Neurons
Published on: December 22, 2023
Related Concept Videos
Alzheimer's Disease: Overview
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ and tau...
Pharmacogenomics: Identification of New Drug Targets
Alzheimer Disease l: Introduction
Alzheimer Disease ll: Pathophysiology
